400-900-4166

Recombin human HLA-DRB4 protein,BR

Recombinant human HLA-DRB4 protein

(订货以英文名为准)
产品编号:AC82769 品牌:Acmec
中文名称:
Recombin human HLA-DRB4 protein
英文名称:
Recombinant human HLA-DRB4 protein
保存条件:
-20°C

产品属性 Product Attributes

基本信息

基因名: HLA-DRB4
别名: DR beta 4 chain
全名: HLA class II histocompatibility antigen,DR beta 4 chain
英文名称: Recombinant human HLA-DRB4 protein
中文名称: HLA-Ⅱ类组织相容性抗原DR-β4链
规格: 10ug ; 50ug ; 100ug ; 1mg
外观:(性状) Powder: Lyophilized from a 0.2 μm filtered solution of 2-8M Urea, 20mM Tris-HCl, 150mM NaCl, 1mM DTT, PH7.2-8.0. (Or liquid with 5% glycerol.)
纯度: ≥85% by SDS-PAGE.
储存条件: Reconstituted protein solution can be stored at 4-7°C for 1-2 weeks, stored at < -20°C for 1 year.
运输条件: The product is shipped at -20°C temperature. Upon receipt, store it immediately at the temperature listed below.
浓度: 1mg/ml by SDS-PAGE.

产品信息

Swiss Prot: P13762
Gene ID: 3126
交叉反应: Human
分子量: 30kDa
区间范围: 1-266aa
背景说明: Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells.The peptide binding cleft accommodates peptides of 10-30 residues.The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases.Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and for this reason this antigen presentation pathway is usually referred to as exogenous.As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments, exogenous antigens must compete with those derived from endogenous components.Autophagy is also a source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments.In addition to APCs, other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecules and CD74 and act as APCs, which is an unusual trait of the GI tract.To produce a MHC class II molecule that presents an antigen, three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form a heterononamer.Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a small fragment termed CLIP (class-II-associated invariant chain peptide).The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released.HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound.The MHC II molecule bound to a peptide is then transported to the cell membrane surface.In B-cells, the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO.Primary dendritic cells (DCs) also to express HLA-DO.Lysosomal microenvironment has been implicated in the regulation of antigen loading into MHC II molecules, increased acidification produces increased proteolysis and efficient peptide loading.
应用: Immunology research
来源: E.coli

其它标识

纯化方法: NI-NTA affinity purification
溶剂: Reconstituted protein solution can be diluted with distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. (It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water.)
内毒素: Not measured
生物活性: N0
标签信息: With a 6×His tag at the N/C-terminus.

产品介绍 Product Introduction

暂无数据

注意事项 Considerations

1.本产品仅供科研使用。请勿用于医药、临床诊断或治疗,食品及化妆品等用途。请勿存放于普通住宅区。
2.为了您的安全和健康,请穿好实验服并佩戴一次性手套和口罩操作。
3.实验结果可由多种因素影响,相关处理只限于产品本身,不涉及其他赔偿。
危化品级别:
关于的化合物详细属性等信息,点击“
技术资料
DATA SHEET
历史浏览记录
​Copyright ◎ 2018 ACMEC-E.COM-版权所有,未经授权禁止拷贝本站资料,如有违反,将追究法律责任
上海吉至生化科技有限公司
沪公网安备31012002005909号   沪ICP备18007380号-1
本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用。
危险品化学品经营许可证    营业执照(三证合一)